

Advances in Biochemistry in Health and Disease

Devendra K. Agrawal
Ranko Škrbić
Miloš P. Stojiljković
Dragan M. Djuric *Editors*

Cardiovascular Toxicity

Incidence, Pathogenesis and Treatment
Strategies

 Springer

Advances in Biochemistry in Health and Disease

Volume 33

Series Editor

Naranjan S. Dhalla, Institute of Cardiovascular Sciences, St. Boniface Hospital, Winnipeg, Canada

Editorial Board Members

Roberto Bolli, Department of Medicine and Cardiology, University of Louisville, Louisville, USA

Ramesh Goyal, Delhi Pharmaceutical Sciences and Research, New Delhi, India

Chandrasekharan Kartha, Cardiovascular Diseases and Diabetes Biology, Kerala Institute of Medical Sciences, Thiruvananthapuram, India

Lorrie Kirshenbaum, St. Boniface General Hospital, Winnipeg, Canada

Naoki Makino, Kyushu University, Fukuoka, Japan

Jawahar L. L. Mehta, Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, USA

Bohuslav Ostadal, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

Grant N. Pierce, St. Boniface General Hospital, Winnipeg, Canada

Jan Slezak, Institute for Heart Research, Slovak Academy of Sciences, Karlova Ves, Slovakia

Andras Varro, Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary

Karl Werdan, Martin Luther University Halle-Wittenber, Halle (Saale), Germany

William B. Weglicki, School of Medicine and Health Sciences, George Washington University, Washington, USA

Advances in Biochemistry in Health and Disease focus on the latest developments in biochemical research with implications for health and disease. This book series consists of original edited volumes and monographs, presented by leading experts in the field and provides an up to date and unique source of information for all those interested in the fundamental, biochemical processes of the latest and emerging topics and techniques.

Covering a wide variety of topics, this book series is a valuable source of information from those at the lab bench through to the Health Care workers.


Devendra K. Agrawal • Ranko Škrbić •
Miloš P. Stojiljković • Dragan M. Djuric
Editors


Cardiovascular Toxicity

Incidence, Pathogenesis and Treatment
Strategies

 Springer

Editors

Devendra K. Agrawal 
Department of Translational Research
Western University of Health Sciences
Pomona, CA, USA

Ranko Škrbić 
Faculty of Medicine
University of Banja Luka
Banja Luka, Bosnia and Herzegovina

Miloš P. Stojiljković
Faculty of Medicine
University of Banja Luka
Banja Luka, Bosnia and Herzegovina

Dragan M. Djuric
Faculty of Medicine
University of Belgrade
Belgrade, Serbia

ISSN 2512-2142

ISBN 978-3-031-90597-1

<https://doi.org/10.1007/978-3-031-90598-8>

ISSN 2512-2150 (electronic)

ISBN 978-3-031-90598-8 (eBook)

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2025

Advances in Biochemistry in Health and Disease

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

If disposing of this product, please recycle the paper.

Preface

The physiological function of cardiovascular system in the body is the most critical pillar of human well-being. The heart and blood vessels play a major role in thermoregulation, transporting nutrients, gases, and waste products to body organs, maintain fluid balance within the body, and protect the body from infection and blood loss. Indeed, the cardiovascular diseases are the leading cause of morbidity and mortality. Pharmaceuticals, illicit drugs, toxins, poisons, and several environmental factors can induce toxic and adverse effects on the heart and blood vessels, leading to structural changes that impair the blood flow and circulation. Thus, the cardiovascular toxicity due to these factors is the culprit of the global surge in the rate and incidence of cardiovascular diseases and can significantly contribute to the overall burden of cardiovascular diseases. Co-morbidities, such as diabetes and obesity, epigenetic factors, and viral, bacterial, and parasite infections further enhance the cardiovascular toxicity. Thus, it is critical to recognize and understand the factors involved in the pathogenesis of cardiovascular toxicities and develop better therapeutic approaches.

The advent of new drugs and vaccines has been a boon in the treatment of various diseases. However, many drugs and vaccines can induce adverse effects, either directly or indirectly, by affecting the endothelium, coagulation factors, and platelet activation and thus inducing prothrombotic response, inducing oxidative stress and inflammation, interfering with the baroreceptors that regulate blood pressure and cardiovascular variability, altering the regulation of autonomic cardiovascular control, and disrupting electrophysiology and contractility. Unfortunately, this has been ignored for a long time and only lately realized with the attention and initiatives to expand and disseminate knowledge to general population and health practitioners, expand research activities to investigate the underlying cellular and molecular mechanisms, and develop better preventive and treatment strategies.

Cardiovascular adverse effects can be induced by many drug classes used in cancer treatment, such as kinase and proteasome inhibitors, as well as bacterial and viral infections, disorders of central nervous system and gastrointestinal system, and other inflammatory diseases. It is critical to understand the underlying mechanisms

of the cardiovascular toxicity and how to prevent it. What are the effects of different genetics, epigenetics, and chemical, physical, and biological influences in cardiovascular toxicity?

In this very timely topic, a comprehensive and up-to-date information in a critical manner is presented on relevant topics related to incidence, pathogenesis, and treatment strategies of cardiovascular toxicity. The major complications due to chemotherapeutic agents and drugs used in the treatment of allergy, diabetes, inflammatory bowel disease, psychiatric problems, viral infections, and others may encompass a large spectrum of disorders, including the trigger or the development of arrhythmia/QTc Prolongation, atrial flutter, atrial and ventricular fibrillation, atrio-ventricular block, heart failure, hypertension, myocardial infarction, myocarditis, toxic myocardial injury, pericardial disease, peripheral and cerebrovascular ischemia, sinus tachycardia, thromboembolic events leading to limb ischemia, transient ischemic attack, stroke, valvular heart disease, vasculitis, and venous injury. Distinguished scientists, physicians, and surgeons from all over the world with expertise in the fields of cardiovascular diseases, cancer, and other diseases contributed their knowledge and expertise. The biological system in health and disease is complex and dynamic. It is therefore critical to better understand the biological complexity, interactions between genetic–epigenetic–environmental factors, interconnecting genes, interplay of proteins in the cellular and molecular responses in the underlying pathophysiologic mechanisms, and biologic pathways in cardiovascular toxicity. This information is clinically relevant in the mitigation and management of cardiovascular complications for prediction, prevention, and treatment. The identified gaps in our knowledge provide future directions for further investigation.

This book presents a total of 40 chapters that are divided into sub-sections titled “Disease- and Drug-Induced Cardiovascular Toxicity: Incidence and Underlying Pathophysiological Mechanisms,” “Toxins and Poison-induced Cardiovascular Toxicity,” “Genetics, Epigenetics, Environmental Pollution and Nutritional Effects in the Pathogenesis of Cardiovascular Toxicity,” and “Prevention, Management and Treatment of Cardiovascular Toxicity.”

The presented information will be a key resource for knowledge and guidance to researchers in the fields of cardiovascular, cancer, and other diseases, as well as healthcare professionals, including physicians, physician-assistants, nurses, nurse practitioners, pharmacists, and academics interested in public health. This compilation will be ideal as a textbook in various undergraduate, graduate, and postgraduate courses in the public health program, cardiovascular diseases, chemotherapeutic agents and cardiovascular toxicity, cardiovascular toxicity in infectious disease, the pathogenesis of drug-induced cardiovascular toxicity, seminars on cardiovascular toxicity, and epigenetics and genetics in the effect of drugs on cardiovascular toxicity.

Pomona, CA, USA
Banja Luka, Bosnia and Herzegovina
Banja Luka, Bosnia and Herzegovina
Belgrade, Serbia

Devendra K. Agrawal
Ranko Škrbić
Miloš P. Stojiljković
Dragan M. Djuric

Contents

Part I Drug-Induced Cardiovascular Toxicity: Incidence and Underlying Pathophysiological Mechanisms

1	Transient Ischemic Attack and Stroke in Cardiovascular Toxicity	3
	Shreyas Melanahalli and Devendra K. Agrawal	
2	Cardiac Dysfunction and Heart Failure Caused by Cancer Therapy-Induced Cardiotoxicity	23
	Raluca Șoșdean, Silvia Giuchici, Loredana N. Ionică, Adina V. Furdui-Lința, Adrian Sturza, Danina M. Muntean, Daniel F. Lighezan, and Roberto Bolli	
3	Echocardiographic Aspects in Cardio-oncology	51
	Mihaela-Daniela Valcovici, Bogdan Lolescu, and Daniel Marius Duda Seiman	
4	Arrhythmia/QTc Prolongation in Cardiotoxicity	61
	Antoinette Oliveira Blackman, Beatriz Montenegro Oliveira, Suellen Keyze Almeida Lima, and José Sobral Neto	
5	Impact of Cardiotoxicity on Cardiac Bioenergetics	77
	Megan Young and Dunja Aksentijevic	
6	Shared Pathophysiologic Mechanisms Between Cancer and Pulmonary Hypertension	89
	Sumner Gardner, Faris Abusharkh, and Vineet Agrawal	
7	Cardiovascular Toxicity of Catecholamines	111
	Miloš P. Stojiljković, Dragana Lončar-Stojiljković, Sonja T. Marinković, Milovan Bojić, and Ranko Škrbić	

8	Effect of Antipsychotic and Antidepressant Drugs in Cardiovascular Toxicity	131
	Marija Stojanovic and Devendra K. Agrawal	
9	Cardiovascular Toxicity in Diabetes Mellitus: Focus on Diabetogenic and Anti-diabetogenic Agents	153
	Nina M. Radisavljevic, Slavica S. Mutavdzin Krneta, and Dragan M. Djuric	
10	Diabetic Foot Ulcer and Cardiac Autonomic Neuropathy	205
	Vikrant Rai	
11	Statins and Cardiotoxicity	217
	Victor Gurevich and Andrey Obrezan	
12	Anesthetics and Cardiovascular Toxicity	231
	Marko Djuric and Irina Nenadic	
13	Anti-inflammatory Bowel Diseases Drugs and Cardiovascular Toxicity	253
	Uglješa Maličević and Devendra K. Agrawal	
14	Antiviral Therapy and Cardiovascular Toxicity	271
	Wilson S. Tang and David Jesse Sanchez	
15	Immune Checkpoint Inhibitors and Myocarditis: Clinical Impact and Underlying Mechanisms	281
	Ali Moradi, Naya Said, Sina Khoshniyat, Kurt Ramey, Stefan Longobardi, and Robert Subbiondo	
16	Hormonal Therapy and Cardiotoxicity in Prostate Cancer Patients	295
	Sakthivel Muniyan, Lei Xi, Arun Samidurai, Anindita Das, Rakesh C. Kukreja, and Surinder K. Batra	
17	Doxorubicin Induced Mitochondrial Dysfunction and Cardiotoxicity	321
	Sukhwinder K. Bhullar, Raneeta Thingnam, Inna Rabinovich-Nikitin, and Lorrie A. Kirshenbaum	
18	Ponatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Efficacy, Mechanisms, and Cardiotoxic Challenges	335
	Jonatas M. Rolando and Dinender K. Singla	
19	Nutrient-Drug Interactions and Cardiotoxicity in Oncologic Patients	361
	Simona Dragan, Dana Man, and Nilima Rajpal Kundnani	

Part II Toxins and Poison-Induced Cardiovascular Toxicity

20	Cardiotoxicity of Pesticides	387
	Biljana Antonijević and Miloš P. Stojiljković	
21	Cardiotoxicity of Gaseous Poisons	401
	Marijana Curcic, Evica Antonijević Miljaković, and Biljana Antonijević	
22	Cardiovascular Toxicity of Volatile Organic Compounds	415
	Evica Antonijević Miljaković, Marijana Curcic, and Biljana Antonijević	
23	Cardiovascular Toxicity of Metals	427
	Zorica Bulat and Petar Bulat	
24	Excess Labile Zinc Ion Produces Toxic Effects in Cardiac Cells Through Oxidation and/or Phosphorylation of Proteins and Kinases	443
	Belma Turan	
25	Persistent Organic Pollutants and Cardiotoxicity	469
	Aleksandra Buha Đorđević	
26	Cardiovascular Toxicity of Natural Toxins	485
	Danijela Đukić-Ćosić	

Part III Genetics, Epigenetics, Environmental Pollution and Nutritional Effects in the Pathogenesis of Cardiovascular Toxicity

27	Predisposing Role of Genetic and Epigenetic Factors in the Pathogenesis of Drug-Induced Cardiovascular Toxicity	505
	Yssel Mendoza-Mari and Devendra K. Agrawal	
28	Pharmacogenetics and Pharmacogenomics in the Prediction of Cardiovascular Toxicity	523
	Ranko Škrbić, Lana Nežić, and Miloš P. Stojiljković	
29	Environmental Noise and Outdoor Light Pollution in the Pathogenesis of Cardiovascular Toxicity	555
	Zubair Ahmed, Fihri Chaudhary, and Devendra K. Agrawal	
30	Nutrition, Gut Microbiota, and the Pathogenesis of Cardiovascular Toxicity	585
	Mohamed M. Radwan	

Part IV Prevention, Management and Treatment of Cardiovascular Toxicity	
31 Heart-Derived Stromal Cells and In Vitro 3D Models in Cardiotoxicity Assessment	601
Dongwei Sun and Finosh G. Thankam	
32 Circulating Biomarkers in the Detection of Cardiovascular Toxicity	621
Sanja Stankovic, Nina M. Radisavljevic, Zorislava Bajic, Marija Polovina, and Dragan M. Djuric	
33 Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery	659
Melchior Luiz Lima	
34 Modulation of Drug-Induced Oxidative Stress in Cardiovascular Toxicity	699
Spencer Collins, Marcel P. Fraix, and Devendra K. Agrawal	
35 The Effect of Molecular Hydrogen on the Mitigation of Oxidative Stress in Cardiovascular Disorders	733
Ján Slezák, Tatiana Ravingerova, and Branislav Kura	
36 SUR2A: A Potential Cornerstone for Cardioprotection	749
Aleksandar Jovanović	
37 Repurposing of PARP Inhibitors for the Clinical Management of Acute Cardiotoxicity	763
Ferenc Gallyas Jr, Robert Halmosi, and Kalman Toth	
38 Potential Role of Nutraceuticals in the Prevention of Cardiovascular Toxicity	793
Resmi Rajalekshmi and Devendra K. Agrawal	
39 Role of Tadalafil in Mitigating Cardiotoxicity Induced by Cancer Chemotherapy	821
Saisudha Koka, Inavolu Sriram Sandeep, and Rakesh C. Kukreja	
40 Physical Medicine and Rehabilitation Strategies in Cancer Treatment-Induced Cardiotoxicity	841
Manas Aavula, Sugeeth Kandikattu, Devendra K. Agrawal, and Marcel P. Fraix	
Index	865

Editors and Contributors

About the Editors



Devendra K. Agrawal holds multiple degrees, including MSc, PhD (Biochemistry), PhD (Medical Sciences), MBA, and MS (Information Technology and Management). He has served on several academic positions, including Clinical Biochemist, Professor, Founding Chairman of the Department of Clinical and Translational Science, Senior Associate Dean of Clinical and Translational Sciences, and Senior Vice President for Research and Biotechnology. Currently, Dr. Agrawal serves as Professor and Director, Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA.

Dr. Agrawal is a member of the *Alpha Omega Alpha Honor Medical Society* and a Fellow of the AAAAI, AHA, APS, and IACS. He has been recognized with many awards, including the highest teaching award at Creighton University, Distinguished Research Career Award, Distinguished Professor Award, Distinguished Faculty Service Award, University Research Award, Distinguished Mentor Award, *Professor Bohuslav Ostadal Award* for Excellence in Cardiovascular Sciences, *Distinguished Leadership Award*, *Ricardo Gelpi Award*, *Andras Varro Award*, *Harpal Buttar Award for Excellence in Cardiovascular Sciences*, and *Cardiovascular Sciences Innovative Research Award*. Dr. Agrawal has been an invited speaker at many prestigious national and international scientific meetings. Dr. Agrawal is serving on the position of Secretary

General and Treasurer of the International Academy of Cardiovascular Sciences—North American section and the Director and Treasurer of the Academy of Cardiovascular Sciences Foundation USA, Inc.

Dr. Agrawal has served on many grant review panels, including the VA Merit Review, DoD, NIH-NIAID, NIH-NHLBI, MRC-UK, and US-Israel BSF Grant Review Committees, as well as the Science Foundation Ireland, Austrian Science Fund, British Lung Foundation, Swiss NSF, ViCi Netherlands, and the Asthma Research Foundation of Western Australia. Dr. Agrawal has served or is currently serving as an associate editor and on the editorial board of several prestigious journals. Dr. Agrawal contributed to science by publishing over 620 original research articles in peer-reviewed journals and book chapters. He has co-edited books on various topics, including allergy, asthma, and immunology, COVID-19 and stem cells, environmental factors in the pathogenesis of cardiovascular diseases, and flow cytometry. His major research areas include the cellular, molecular, and immunobiology of coronary and carotid artery disease, stem cell therapy, shoulder rotator cuff injuries, traumatic brain injury, diabetes and diabetic foot ulcers, renal diseases, and allergy and bronchial asthma. NIH funds his research educational programs and projects.

Dr. Agrawal has trained over 250 medical students, many of whom are now academic physician-scientists, and directly supervised and guided 73 graduate students to earn MD-PhD, MD-MS, MS, and PhD degrees, 74 postdoctoral fellows, and 15 assistant professors, many of whom are currently on high positions in academia and industries. Many clinical residents, fellows, and research investigators have received training under his direct supervision. He is passionate to train and mentor next generation of clinical and translational researchers.



Ranko Škrbić graduated in 1986 and received the MD degree from the Faculty of Medicine, University of Banja Luka, Bosnia and Herzegovina (ex-Yugoslavia), and MSc degree in 1991 from the Faculty of Natural Sciences, Zagreb University, Croatia. As a Japanese Government Research fellow, he spent 1 year at Shinshu University School of Medicine studying cardiovascular pharmacology. In 1994, he received his PhD degree from the Faculty of Medicine, Belgrade University, Serbia, and in the year 2000 the Clinical Pharmacology Specialist degree from the Faculty of Medicine, Novi Sad University, Serbia. He has also attended several short-term courses and trainings, including drug information training at Bristol Royal Infirmary, Bristol, UK in 1999; short-term course in pharmacoeconomics at the London School of Economics (LSE), London, UK; and a training in health management, the World Bank's Basic Health Project for Bosnia and Herzegovina, organized in collaboration with Imperial College London, UK, and Heidelberg University, Germany.

Dr. Škrbić is a Full Professor of Pharmacology, Toxicology, and Clinical Pharmacology since 2009. Notably, his professional career includes the following positions: Head of the Department of Pharmacology, Faculty of Medicine, University of Banja Luka (2002–2009); Head of the National Drug Information Centre, established in collaboration with WHO and EU-ECHO (1998–2006); Chairman of the Drug Registration Committee of the Republic of Srpska, Bosnia and Herzegovina (1999–2002); EU PHARE Regional Coordinator for Pharmaceutical Sector Development in Bosnia and Herzegovina (1998–1999); UNICEF Regional Coordinator for Essential Drugs and Rational Drug Use in the Republic of Srpska, Bosnia and Herzegovina (1999–2000); EU-CARDS Regional Coordinator for Health Care Reform in Bosnia and Herzegovina (2000–2002); Short-term consultant for the Development of Accreditation Standards and Clinical Guidelines, EPSILON Research, Development and Consulting, doo, Banja Luka (Basic Health Project of the World Bank; Accreditation and Quality Assurance) (2001–2003); Minister of Health and Social Welfare, Government of the Republic of Srpska, Bosnia and Herzegovina (2005–2013); Ambassador of Bosnia and

Herzegovina in Serbia (2013–2015); and Dean of the Faculty of Medicine, University of Banja Luka (2016–now).

Dr. Škrbić was the Founder and Chair of the PhD Program in Biomedical Sciences at the Faculty of Medicine, University of Banja Luka (2015); Visiting Professor, Faculty of Medicine, Belgrade University, Serbia (since 2019); and Visiting Professor at the First Moscow State Medical University, Moscow, Russia (2024). Dr. Škrbić has organized and chaired several international conferences, including *The 6th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries*, Banja Luka, Bosnia and Herzegovina, June 16–20, 2004; *The Third Health Ministers' Forum: Health in All Policies in South-eastern Europe—A Shared Goal and Responsibility*, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina, October 13–14, 2011; *The International Conference on Medical and Biological Engineering 2019 (CMBEBIH 2019)*, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina May 16–19, 2019; and *The 7th Meeting of the European Section and 8th Meeting of North American Section of the International Academy of Cardiovascular Sciences (IACS)*, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina, September 20–23, 2021

Dr. Škrbić is a member of several professional societies, including the Serbian Pharmacological Society, the Section for toxicology of the Serbian Medical Association, and the Association of Clinical Pharmacological Societies with Sections of Clinical Pharmacists and Pharmacoinformatics of Bosnia and Herzegovina. He is also an Honorary Member of the Cardiology Society of Serbia. Additionally, he serves as the President of the Association for Atherosclerosis and Cardiovascular Research, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina. He is a Fellow of the International Academy of Cardiovascular Sciences (FIACS) and a Member of the Executive Council of the International Academy of Cardiovascular Sciences, European Section (IACS-ES). He is also a member of the Academy of Science and Arts of the Republic of Srpska. He has served as the associate editor or the member of editorial board of the several prestigious international journals.

Dr. Škrbić is the founder and head of the Centre for Biomedical Research, established in 2018 within the Faculty of Medicine, Banja Luka University. His research has been recognized mostly in the areas of cardiovascular pharmacology, pharmacoepidemiology, inflammation, ischemia-reperfusion injury, cardioprotection, and pharmacogenetics. Over the past 10 years, Dr. Škrbić's Centre has made significant contributions to the field by studying various well-established experimental methods and translating them into clinical practice. He has published more than 120 publications in peer-reviewed international journals, authored 4 chapters in international textbooks/monographs, and edited/co-edited 15 monographs/books.

Dr. Škrbić is a recipient of several awards and honors, including a Fellowship of the International Academy of Cardiovascular Sciences (IACS), the IACS Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery (2021), the Gold Medal for outstanding leadership in cardiovascular sciences (2022), a special award from the Ministry of Foreign Affairs of Japan (2021), and the Ricardo Gelpi Award for Excellence in Cardiovascular Sciences (2024).

Miloš P. Stojiljković, MD, PhD, FIACS holds MSc and PhD degrees. He is an experienced biomedical researcher who discharged numerous research, teaching, and managerial duties, including clinical pharmacologist, assistant professor, associate professor, and full professor of pharmacology, toxicology, and clinical pharmacology, as well as Vice-Dean for Scientific Research. Currently, Dr. Stojiljković is the Professor and Director, PhD Programme, Faculty of Medicine, University of Banja Luka.

Dr. Stojiljković was a Postdoctoral Fellow at the Medical University of South Carolina. He is a Fellow of the International Academy of Cardiovascular Sciences (IACS) and member of several distinguished scientific societies, such as German Society for Experimental and Clinical Pharmacology and Toxicology, British Pharmacological Society. He has been recognized with many awards, including several publication rewards from the Faculty of Medicine,

University of Banja Luka and *Distinguished Leadership Award* and *Vincenzo Panagia Distinguished Lecture Award* from the IACS. Dr. Stojiljković has been an invited speaker at many prestigious national and international scientific meetings. Dr. Stojiljković is currently a member of the Council of the IACS-European section.

Dr. Stojiljković has been serving as Editor-in-Chief of the biomedical journal *Scripta Medica* and as Associate Editor of the renowned international journals *Drug and Chemical Toxicology* and *Molecular and Cellular Biochemistry*. Dr. Stojiljković contributed to science by publishing over 200 original research articles in peer-reviewed journals and book chapters. His major research areas include the toxicology of carbamate and organophosphate acetylcholinesterase inhibitors, the influence of lipids on blood pressure, and the use of various chemical substances in cardioprotection.

Dr. Stojiljković has been an experienced teacher for 37 years and is dedicated to training and mentoring younger researchers.



Dragan M. Djuric earned his MD degree in 1987, an MS degree in 1991, a PhD degree in 1993, and a Clinical Physiologist degree in 2007, all from the Faculty of Medicine, University of Belgrade (Belgrade, Serbia). He finished his postdoctoral training in Germany at the Max Planck Institute for Physiological and Clinical Research and Kerckhoff Klinik GmbH, Bad Nauheim (1998 and 2001–2002) and in the USA at the Department of Physiology, College of Medicine, University of South Alabama, Mobile (2000). After serving in several academic positions, including Director and Chair, Institute of Medical Physiology, Faculty of Medicine, University of Belgrade (2006–2012), Founder and Chair, PhD Program in Physiological Sciences (2009–2024), leadership positions in Serbian Physiological Society (2003–2021), the FEPS Task Force Group on Education in Physiology (2007–2008), and national atherosclerosis societies (since 1998), he is currently a Professor of Medical Physiology, Faculty of Medicine, University of Belgrade (Belgrade, Serbia), and a Visiting Professor, Faculty of Medicine, University of Banja Luka (Bosnia and Herzegovina) (since 2019). Dr. Djuric is a Fellow of IACS and IUPS Academy of Physiology. He has been recognized with many awards, including

the Naranjan Dhalla Award for Innovative Investigators in Cardiovascular Sciences (2024), the Oration Award from Prof. Harpal Buttar (2024), the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research (2022), the James Willerson Award for Excellence in Cardiovascular Sciences (2021), the Distinguished Leadership Award in Cardiovascular Sciences (2019), the Andras Varro Award for Excellence in Cardiovascular Sciences (2018), and the Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery (2015), all from the International Academy of Cardiovascular Sciences (IACS), including European, North American, and Indian sections. Additionally, he has been honored with the Serbian Physiological Society Award for Lifetime Achievement in Physiological Sciences (2016); the Samuel Racz Medal and Honorary Membership for his contributions to physiology from the Hungarian Physiological Society (2010); Honorary Membership, Bulgarian Society for Cell Biology (2009); Honorary Membership, Romanian Society for Laboratory Medicine (2008); the Medal of the Yugoslav Society of Cardiology (2002); and the Belgrade City October Award (1987). Dr. Djuric has served on the editorial boards of several prestigious journals and in a few grants review panels. He was a reviewer in many journals, books, and meeting abstracts. Dr. Djuric contributed to science by publishing over 300 original research, review and editorial articles in peer-reviewed journals and book chapters. He has edited/co-edited 6 books on medical physiology, 7 monographs on endothelium, vascular biology, atherosclerosis, and nutrition, including Springer Nature book entitled *Environmental Factors in the Pathogenesis of Cardiovascular Diseases* (2024), 15 abstracts from scientific meetings which he organized/co-organized, and served as guest editor for 13 special or topic issues of prestigious international journals. He has been an invited speaker at many prestigious national and international scientific meetings and academic institutions. Dr. Djuric has trained over 30 medical students in research work and has directly supervised and guided 20 graduate students in earning their MD-MS and MD-PhD degrees. The National Ministry of Education, Science and Technological Development and EU COST funded his research projects. His major research areas

include cardiovascular research, cardioprotection, experimental cardiometabolic models, endothelial dysfunction, experimental vascular models, gasotransmitters and oxidative stress, homocysteine and related vitamins, nutraceuticals, micronutrients and cardiovascular health, risk factors and cardiovascular health, vascular reactivity, mediators of inflammation, atherosclerosis, and environmental factors in the pathogenesis of cardiovascular diseases.

Contributors

Manas Aavula Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Faris Abusharkh Vanderbilt University, Nashville, TN, USA

Devendra K. Agrawal Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Vineet Agrawal Vanderbilt University, Nashville, TN, USA
Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA

Zubair Ahmed Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Dunja Aksentijevic William Harvey Research Institute, Barts Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK

Biljana Antonijević University of Belgrade—Faculty of Pharmacy, Toxicological Risk Assessment Center, Belgrade, Serbia
Department of Toxicology “Akademik Danilo Soldatović”, University of Belgrade—Faculty of Pharmacy, Belgrade, Serbia

Zorislava Bajic Department of Physiology, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Surinder K. Batra Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA

Sukhwinder K. Bhullar Department of Physiology and Pathophysiology, The Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada

Department of Pharmacology and Therapeutics, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Antoinette Oliveira Blackman University Center of Central Planalto Aparecido dos Santos—UNICEPLAC, Gama, Federal District, Brazil

University Center of Brasilia—CEUB, Brasilia, Federal District, Brazil

University Center Euro American—UNIEURO, Brasília, Brazil

Milovan Bojić Institute for Cardiovascular Diseases “Dedinje”, Belgrade, Serbia

Roberto Bolli Institute of Molecular Cardiology, University of Louisville Physicians Outpatient Center, Louisville, KY, USA

Petar Bulat University of Belgrade—Faculty of Medicine, Belgrade, Serbia
Serbian Institute of Occupational Health, Belgrade, Serbia

Zorica Bulat Department of Toxicology “Akademik Danilo Soldatović”, University of Belgrade—Faculty of Pharmacy, Belgrade, Serbia

Fihir Chaudhary Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Spencer Collins Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Marijana Curcic Department of Toxicology “Akademik Danilo Soldatović”, University of Belgrade—Faculty of Pharmacy, Belgrade, Serbia

Anindita Das Pauley Heart Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

Dragan M. Djuric Faculty of Medicine, Institute of Medical Physiology “Richard Burian”, University of Belgrade, Belgrade, Serbia

Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Marko Djuric Clinic for Anesthesiology and Intensive Care, University Clinical Hospital Center “Dr Dragisa Misovic-Dedinje”, Belgrade, Serbia

Department of Anesthesiology, Reanimatology and Intensive Care, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Aleksandra Buha Đorđević Department of Toxicology “Akademik Danilo Soldatović”, Faculty of Pharmacy, University of Belgrade, Belgrade, Republic of Serbia

Simona Dragan Department of Cardiology, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

Danijela Đukić-Ćosić Department of Toxicology “Akademik Danilo Soldatović”, Centre for Toxicological Risk Assessment, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

Marcel P. Fraix Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA
Department of Physical Medicine and Rehabilitation, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA
Section of Health Policy and Management, Department of Population Health Science, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Adina V. Furdul-Lința Department of Functional Sciences—Chair of Pathophysiology, Centre for Translational Research and Systems Medicine, “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania

Ferenc Gallyas Jr Department of Biochemistry and Medicinal Chemistry, Medical School, University of Pecs, Pecs, Hungary

Sumner Gardner Vanderbilt University, Nashville, TN, USA

Silvia Giuchici Department of Functional Sciences—Chair of Pathophysiology, Centre for Translational Research and Systems Medicine, “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania

Victor Gurevich Center of Atherosclerosis and Lipid Disorders, Saint-Petersburg State University, Medical Institution, St. Petersburg, Russia
Nord-Western State Medical University n.a. I.I. Mechnikov, Center of Atherosclerosis and Lipid Disorders, St. Petersburg, Russia

Robert Halmosi First Department of Internal Medicine, Clinical Centre, University of Pecs, Pecs, Hungary

Loredana N. Ionică Department of Internal Medicine—First University Clinic of Medical Semiotics, “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania

Aleksandar Jovanović Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus
Center for Neuroscience and Integrative Brain Research (CENIBRE), University of Nicosia Medical School, Nicosia, Cyprus

Sugeeth Kandikattu Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Sina Khoshniyat Biomedicine, School of Sciences, La Trobe University, Melbourne, Australia

Lorrie A. Kirshenbaum Department of Physiology and Pathophysiology, The Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada

Department of Pharmacology and Therapeutics, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Saisudha Koka Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Kingsville, TX, USA

Rakesh C. Kukreja Pauley Heart Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

Division of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA

Nilima Rajpal Kundnani Department of Cardiology, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

Branislav Kura Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia

Daniel F. Lighezan Department of Internal Medicine—First University Clinic of Medical Semiotics, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania

Melchior Luiz Lima Centrocor—Heart Clinic Ltd., Vitória, ES, Brazil

Suellen Keyze Almeida Lima University Center of Central Planalto Aparecido dos Santos—UNICEPLAC, Gama, Federal District, Brazil

Bogdan Lolescu Department of Cardiology, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

Dragana Lončar-Stojiljković Institute for Cardiovascular Diseases “Dedinje”, Belgrade, Serbia

Department of Anaesthesiology and Intensive Medicine, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Stefan Longobardi Internal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, FL, USA

Uglješa Maličević Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA

Department of Pathophysiology and Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Dana Man Department of Cardiology, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

Sonja T. Marinković Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Paediatric Clinic, University Clinical Centre of the Republic of Srpska, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Shreyas Melanahalli Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Yssel Mendoza-Mari Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Evica Antonijević Miljaković University of Belgrade—Faculty of Pharmacy, Toxicological Risk Assessment Center, Belgrade, Serbia
Department of Toxicology “Akademik Danilo Soldatović”, University of Belgrade—Faculty of Pharmacy, Belgrade, Serbia

Ali Moradi Internal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, FL, USA

Sakthivel Muniyan Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

Danina M. Muntean Department of Functional Sciences—Chair of Pathophysiology, Centre for Translational Research and Systems Medicine, “Victor Babeş” University of Medicine and Pharmacy, Timișoara, Romania

Slavica S. Mutavdzin Krneta Institute of Medical Physiology “Richard Burian”, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Irina Nenadic Clinic for Anesthesiology and Intensive Care, University Clinical Hospital Center “Dr Dragisa Misovic-Dedinje”, Belgrade, Serbia
Department of Anesthesiology, Reanimatology and Intensive Care, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

José Sobral Neto Centrocord, Brasília, Federal District, Brazil

Lana Nežić Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Andrey Obrezan Center of Atherosclerosis and Lipid Disorders, Saint-Petersburg State University, Medical Institution, St. Petersburg, Russia

Beatriz Montenegro Oliveira University Center of Central Planalto Aparecido dos Santos—UNICEPLAC, Gama, Federal District, Brazil

Marija Polovina Department of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Inna Rabinovich-Nikitin Department of Physiology and Pathophysiology, The Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada

Department of Pharmacology and Therapeutics, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Nina M. Radisavljevic Institute of Medical Physiology “Richard Burian”, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Mohamed M. Radwan Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA

Vikrant Rai Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA

Resmi Rajalekshmi Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA

Kurt Ramey Cardiology, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, FL, USA

Tatiana Ravingerova Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia

Jonatas M. Rolando Division of Metabolic and Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA

Naya Said Center for Translational Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary

Arun Samidurai Pauley Heart Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

David Jesse Sanchez Pharmaceutical Sciences Department, Western University of Health Sciences, Pomona, CA, USA

Inavolu Sriram Sandeep Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Kingsville, TX, USA

Daniel Marius Duda Seiman University of Medicine and Pharmacy, “Victor Babes”, Timisoara, Romania

Dinender K. Singla Division of Metabolic and Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA

Ranko Škrbić Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina

Ján Slezák Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia

Raluca Şoşdean Department of Cardiology—2nd University Clinic of Cardiology, Research Centre of the Institute for Cardiovascular Diseases, “Victor Babeş” University of Medicine and Pharmacy, Timișoara, Romania

Sanja Stankovic Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Marija Stojanovic Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA
Faculty of Medicine, Institute of Medical Physiology “Richard Burian”, University of Belgrade, Belgrade, Serbia

Miloš P. Stojiljković Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
Institute for Cardiovascular Diseases “Dedinje”, Belgrade, Serbia

Adrian Sturza Department of Functional Sciences—Chair of Pathophysiology, Centre for Translational Research and Systems Medicine, “Victor Babeş” University of Medicine and Pharmacy, Timișoara, Romania

Robert Subbiondo Cardiology, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, FL, USA

Dongwei Sun Department of Bioengineering, University of California, Riverside, CA, USA

Wilson S. Tang Pharmaceutical Sciences Department, Western University of Health Sciences, Pomona, CA, USA

Finosh G. Thankam Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

Raneeta Thingnam Department of Physiology and Pathophysiology, The Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada

Department of Pharmacology and Therapeutics, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Kalman Toth First Department of Internal Medicine, Clinical Centre, University of Pecs, Pecs, Hungary

Belma Turan Department of Biophysics, Faculty of Medicine, Lokman Hekim University, Ankara, Turkey

Mihaela-Daniela Valcovici Department of Cardiology, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

Lei Xi Pauley Heart Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

Megan Young William Harvey Research Institute, Barts Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK